The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.
First-line treatment of advanced renal-cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease COMPARZ
Genitourinary Cancers
Renal cell cancer
-
COMPARZ
4
PRELIMINARY SCORE
NI
ADJUSTMENTS
FINAL SCORE
F2c
4
Sunitinib
-
Interferon
Treatment of advanced/metastatic renal cell carcinoma in adults
Genitourinary Cancers
Renal cell cancer
-
-
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Lenvatinib
Everolimus
Everolimus
Treatment of adults with advanced renal cell carcinoma in combination with everolimus following one prior vascular endothelial growth factor (VEGF)-targeted therapy
Genitourinary Cancers
Renal cell cancer
-
-
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Regorafenib
-
Placebo
As monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenibRESORCE
Gastrointestinal Cancers
Hepatobiliary Cancers - Hepatocellular Carcinoma
-
RESORCE
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Nivo/Ipi (nivolumab and ipilimumab)
-
Sunitinib
First-line treatment of adult patients with intermediate/poor-risk advanced RCC CheckMate 214
Genitourinary Cancers
Renal cell cancer
-
CheckMate 214
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Osimertinib
-
Gefitinib or erlotinib
Previously untreated EGFR mutated (exon 19 deletion or L858R)FLAURA
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+ (exon 19 deletion or L858R)
FLAURA
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Alectinib
-
Crizotinib
As monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).ALEX
Thoracic Malignancies
Non-small-cell Lung Cancer
ALK+
ALEX
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Alectinib
-
Chemotherapy (pemetrexed or docetaxel)
As monotherapy is indicated for the treatment of adult patients with ALK‑positive advanced NSCLC previously treated with crizotinibALUR
Thoracic Malignancies
Non-small-cell Lung Cancer
ALK+
ALUR
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Ceritinib
-
Chemotherapy (pemetrexed or docetaxel)
Treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) previously treated with crizotinibASCEND-5
Thoracic Malignancies
Non-small-cell Lung Cancer
ALK+
ASCEND-5
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Ceritinib
-
Chemotherapy
Frist-line treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) stage IIIB/IV ASCEND-4
Thoracic Malignancies
Non-small-cell Lung Cancer
ALK+
ASCEND-4
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Pembrolizumab
Chemotherapy (Pemetrexed)
Chemotherapy
In combination with pemetrexed and platinum chemotherapy for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma in adults whose tumours have no EGFR or ALK positive tumour mutationsKEYNOTE-189
Thoracic Malignancies
Non-small-cell Lung Cancer
-
KEYNOTE-189
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Lorlatinib
-
Single arm
As monotherapy is indicated for the treatment of adult patients with ALK+ advanced NSCLC whose disease has progressed after alectinib or ceritinib as the first ALK TKI therapy; or crizotinib and at least one other ALK TKIB7461001
Thoracic Malignancies
Non-small-cell Lung Cancer
ALK+
B7461001
4
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
4
Olaparib
-
Placebo
Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapySOLO-1
Gynaecological Malignancies
High-grade epithelial ovarian, fallopian tube or primary peritoneal cancer
BRCA mutation
SOLO-1
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Olaparib
-
Placebo
Maintenance therapy in relapsed high-grade cancer of the ovaries, fallopian tubes and peritoneum with BRCA mutations after previous treatment and in whom platinum-based chemotherapy has reduced or cleared the cancerSOLO-2
Gynaecological Malignancies
Ovarian, fallopian tubes and peritoneum cancer
BRCA mutation
SOLO-2
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Pembrolizumab
Axitinib
Sunitinib
First-line treatment of advanced RCC in adultsKEYNOTE-426
Genitourinary Cancers
Renal cell cancer
-
KEYNOTE-426
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
177Lu-DOTATATE
Best supportive care + octreotide
Octreotide
Unresectable or metastatic, progressive, well-differentiated (Grade 1 and Grade 2), somatostatin receptor positive-GEP-NETs in adultsNETTER-1
Endocrine Tumours
Neuroendocrine Tumour - Midgut
-
NETTER-1
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Brigatinib
-
Single arm
Monotherapy for the treatment of adult patients with anaplastic lymphoma kinase ALK positive advanced NSCLC previously treated with crizotinibALTA
Thoracic Malignancies
Non-small-cell Lung Cancer
ALK+
ALTA
4
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
4
Pembrolizumab
Carboplatin and either paclitaxel or nab-paclitaxel
Carboplatin and either paclitaxel or nab-paclitaxel
First-line metastatic squamous non-small cell lung cancer KEYNOTE-407
Thoracic Malignancies
Non-small-cell Lung Cancer
-
KEYNOTE-407
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Abemaciclib
Fulvestrant
Fulvestrant + placebo
Treatment of women with hormone receptor-positive, HER2-negative locally advanced or MBC as initial endocrine-based therapy, or in women who have received prior ET MONARCH 2
Breast Cancer
Breast Cancer
HR+ HER2-
MONARCH 2
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Ribociclib
Fulvestrant
Placebo + fulvestrant
Treatment of women with hormone receptor-positive, HER2-negative locally advanced or MBC as initial endocrine-based therapy, or in women who have received prior ET MONALEESA-3
Breast Cancer
Breast Cancer
HR+ HER2-
MONALEESA-3
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Olaparib
-
Standard chemotherapy
Treatment of patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or MBC who have been previously treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless unsuitable for these treatments OlympiAD
Breast Cancer
Breast Cancer
HER2- g-BrCa+ve
OlympiAD
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Tucatinib
Trastuzumab + capecitabine
Placebo, trastuzumab + capecitabine
HER2-positive locally advanced or metastatic breast cancer after at least 2 prior anti-HER2 treatment regimes HER2CLIMB
Breast Cancer
Breast Cancer
HER2+
HER2CLIMB
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Durvalumab
-
Placebo
Treatment of adult patients with unresectable, stage III NSCLC whose disease has not progressed following concurrent platinum-based CRTPACIFIC
Thoracic Malignancies
Non-small-cell Lung Cancer
PD-L1
PACIFIC
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Abiraterone
Prednisone + ADT (androgen deprivation therapy)
ADT + placebo
Indicated with prednisone or prednisolone for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT)LATITUDE
Genitourinary Cancers
Prostate cancer
-
LATITUDE
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Apalutamide
ADT (androgen deprivation therapy)
ADT + placebo
Treatment of non metastatic castration resistant prostate cancer (nmCRPC) in adult men who are at high risk of developing metastatic diseaseSPARTAN
Genitourinary Cancers
Prostate cancer
-
SPARTAN
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Abiraterone
Prednisone + ADT (androgen deprivation therapy)
ADT + placebo
Indicated with prednisone or prednisolone for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT)STAMPEDE
Genitourinary Cancers
Prostate cancer
-
STAMPEDE
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Enzalutamide
ADT (androgen deprivation therapy)
ADT
Treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapyENZAMET
Genitourinary Cancers
Prostate cancer
-
ENZAMET
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Enzalutamide
ADT (androgen deprivation therapy)
ADT + placebo
Treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC)PROSPER
Genitourinary Cancers
Prostate cancer
-
PROSPER
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Docetaxel
ADT (androgen deprivation therapy)
ADT
In combination with androgen-deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancerCHAARTED
Genitourinary Cancers
Prostate cancer
-
CHAARTED
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Docetaxel
ADT (androgen deprivation therapy)
ADT
In combination with androgen-deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer.CHAARTED
Genitourinary Cancers
Prostate cancer
-
CHAARTED
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Watchlist
Tested Agent(s)
Combined Agent(s)
Control Arm
Therapeutic Indication
Tumour Type
Tumour Sub-type
Tumour Sub-group
Trial Name
Ref.
Score
Scorecard
Scorecard
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.